Aspreva says FDA fast-tracks CellCept lupus drug

(Reuters) - Aspreva is evaluating CellCept for the treatment of lupus
nephritis in a global phase III study. Lupus nephritis is a
complication of systemic lupus erythematosusis involving severe
inflammation of the kidney and may progress rapidly to renal
failure.




Read more at Reuters.com Government Filings News